[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Benha University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":652},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,52,75,105,133,157,185,207,235,260,283,307,331,356,385,406,424,448,473,493,520,543,570,597,619],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100639084","selective-extended-venous-stripping-versus-standard-microsurgical-varicocelectomy-for-varicocele-related-male-infertility-100639084",false,"NCT07605351","Selective Extended Venous Stripping Versus Standard Microsurgical Varicocelectomy for Varicocele-Related Male Infertility","Selective Extended Microsurgical Venous Stripping Versus Standard Microsurgical Subinguinal Varicocelectomy in Infertile Men With Abnormal Semen Parameters: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 18 to 50 years.\n* Couple infertility for at least 12 months.\n* Clinically palpable grade I to III varicocele confirmed by physical examination.\n* Abnormal semen parameters documented on at least two semen analyses performed 2 to 4 weeks apart according to World Health Organization laboratory standards.\n* Female partner evaluation completed or planned, with no untreated severe female factor that would make natural conception impossible.\n* Willingness to comply with postoperative follow-up at 3, 6, and 12 months.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Azoospermia or cryptozoospermia, defined as absence of sperm in the native ejaculate on at least two baseline semen analyses, including cases in which sperm are detected only after centrifugation.\n* Known clinically significant chromosomal or genetic abnormality that independently explains severe male infertility, when identified before enrollment.\n* Previous varicocelectomy of the index side.\n* Previous inguinal, scrotal, or retroperitoneal surgery that may alter spermatic cord anatomy.\n* Subclinical varicocele only.\n* Isolated scrotal pain with normal semen parameters.\n* Hypogonadotropic hypogonadism requiring hormonal induction therapy.\n* Testosterone therapy within the previous 6 months.\n* Use of anti-estrogens, gonadotropins, or aromatase inhibitors within the previous 3 months.\n* Active genitourinary infection.\n* Testicular tumor or history of testicular cancer.\n* Severe systemic disease contraindicating surgery or anesthesia.\n* Inability to provide informed consent.\n* Inability or unwillingness to complete follow-up.","MALE","18 Years","50 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"NA","Varicocele is a common correctable cause of male infertility and may be associated with abnormal semen parameters, impaired testicular function, and scrotal discomfort. Microsurgical subinguinal varicocelectomy is a commonly used surgical approach because it allows careful preservation of the testicular artery, lymphatic channels, vas deferens, and vasal vessels under magnification. However, persistent or recurrent varicocele may still occur after surgery, possibly because of missed or persistent venous channels.\n\nThis randomized controlled trial will compare two surgical techniques in infertile men with clinically palpable varicocele and abnormal semen parameters. Participants will be randomly assigned to either microsurgical subinguinal varicocelectomy with selective extended venous stripping or standard microsurgical subinguinal varicocelectomy with conventional vein ligation and division.\n\nThe main purpose of the study is to determine whether selective extended venous stripping reduces the rate of clinically and Doppler-confirmed persistent or recurrent varicocele at 12 months after surgery compared with the standard microsurgical technique. The study will also compare semen parameter improvement, pain improvement in participants with baseline pain, pregnancy outcomes, operative time, postoperative complications, and the need for additional treatment during 12 months of follow-up.",[28,29],"Varicocele","Male Infertility",[28,29,31,32,33,34,35,36,37,38],"Microsurgical Varicocelectomy","Subinguinal Varicocelectomy","Venous Stripping","Semen Analysis","Scrotal Doppler Ultrasound","Varicocele Recurrence","Abnormal Semen Parameters","Pregnancy Outcome","NOT_YET_RECRUITING","2026-05-18",{"date":42,"type":43},"2026-05-22","ACTUAL",{"date":45,"type":22},"2026-06-15",{"date":47,"type":22},"2028-06-15",{"name":49,"class":50},"Benha University","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":59,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100639139","peng-vs-femoral-nerve-block-for-pain-control-in-hip-surgery-100639139","NCT07597551","PENG vs. Femoral Nerve Block for Pain Control in Hip Surgery","Comparative Study Between Continous Ultrasound Guided Pericapsular Nerve Group (PENG) Block Versus Femoral Nerve Block For Perioperative Pain Control In Hip Surgeries","Inclusion Criteria:\n\n* Aged 40 years or older.\n\n  * Presenting for hip surgeries\n  * No contraindications to regional anesthesia.\n  * Time of surgery up to 3 hours\n  * ASA I-III\n  * Able to provide written informed consent.\n  * Able to reliably report pain and other symptoms to the research team.\n  * Undergoing elective or emergency hip surgeries.\n\nExclusion Criteria:\n\n* Inability to provide first-person consent due to cognitive impairment.\n\n  * Presence of a language barrier that would preclude reliable reporting of symptoms or understanding study procedures.\n  * More than ASA III. 4\n  * Previous neurological deficit in the lower limbs.\n  * Local infection at block area.\n  * Lengthy surgeries more than 3 hours.","ALL","40 Years",{"count":62,"type":22},100,[25],"The aim of this study is to compare the efficacy of the ultrasound- guided pericapsular nerve group (PENG) block versus the femoral nerve block (FNB) for postoperative pain control in patients undergoing hip surgeries, specifically evaluating pain scores and quadriceps strength.",[66],"Pain, Postoperative","2026-05-16",{"date":69,"type":43},"2026-05-19",{"date":71,"type":22},"2026-05-15",{"date":73,"type":22},"2027-05-15",{"name":49,"class":50},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":82,"minAge":83,"maxAge":19,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":51},"100639970","effects-of-extracorporeal-shockwave-therapy-versus-pulsed-electromagnetic-field-therapy-in-females-with-sexual-dysfunction-100639970","NCT07584174","Effects of Extracorporeal Shockwave Therapy Versus Pulsed Electromagnetic Field Therapy in Females With Sexual Dysfunction.","Effects of Extracorporeal Shockwave Therapy Versus Pulsed Electromagnetic Field Therapy in Females With Sexual Dysfunction: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female participants aged 20-50 years diagnosed with female sexual dysfunction (FSFI score \\\u003C26.55), reporting symptoms of reduced sexual desire, arousal dysfunction, orgasmic dysfunction, or dyspareunia.\n2. Premenopausal women in a stable sexual relationship for at least 6 months and sexually active during the previous month.\n3. Symptoms persisting for at least 3 months before enrollment.\n4. Ability to understand study procedures and provide written informed consent.\n5. Willingness to refrain from initiating any additional treatment for sexual dysfunction during the study period\n\nExclusion Criteria:\n\n1. Pregnancy or planned pregnancy during the study period.\n2. Pelvic surgery within the previous 6 months.\n3. Active pelvic inflammatory disease, genital infection, or unexplained vaginal bleeding.\n4. Neurological disorders affecting pelvic floor or sexual function.\n5. Severe pelvic organ prolapse, severe urinary incontinence, or significant pelvic anatomical abnormalities.\n6. Current hormonal therapy or use of medications known to affect sexual function, including antidepressants or antipsychotics.\n7. Severe psychiatric disorders or cognitive impairment limiting participation.\n8. Menopause or perimenopausal status.\n9. Uncontrolled systemic diseases such as diabetes mellitus, hypertension, cardiovascular disease, or thyroid disorders.\n10. Presence of malignancy, pelvic radiation history, or severe chronic pelvic pain disorders.\n11. Contraindications to ESWT or PEMF including cardiac pacemakers or implanted electronic devices, coagulation disorders, anticoagulant therapy, epilepsy, or metal implants in the pelvic region.\n12. Current participation in another clinical trial or receipt of physiotherapy for sexual dysfunction within the previous 3 months.","FEMALE","20 Years",{"count":85,"type":22},90,[25],"This is a prospective, three-arm, parallel-group, assessor-blinded randomized controlled trial designed to compare the effectiveness of extracorporeal shockwave therapy (ESWT) combined with pelvic floor muscle training (PFMT), pulsed electromagnetic field stimulation (PEMF) combined with PFMT, and PFMT alone in Females with sexual dysfunction. Participants will be randomly allocated in a 1:1:1 ratio, and the study duration is 16 weeks, including an 8-week intervention period and an 8-week follow-up period.",[89,90,91,92],"Female Sexual Dysfunction (FSD)","Pelvic Floor Muscle Training","Shock Wave","Pulsed Electromagnetic Therapy",[94,95,96,97],"extracorporeal shock wave therapy","pulsed electromagnetic filed therapy","pelvic floor muscles training","females sexual dysfunction","RECRUITING","2026-05-14",{"date":40,"type":43},{"date":99,"type":43},{"date":103,"type":22},"2027-01-15",{"name":49,"class":50},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":130,"leadSponsor":132,"locationsCount":51},"100637467","telerehabilitation-vs-supervised-physiotherapy-for-medial-epicondylitis-100637467","NCT07582510","Telerehabilitation vs Supervised Physiotherapy for Medial Epicondylitis","Effectiveness of Telerehabilitation Versus Supervised Physiotherapy on Pain, Function, Strength, and Musculoskeletal Ultrasound Parameters in Patients With Medial Epicondylitis: A Randomized Controlled Trial","TELE-ME","Inclusion Criteria:\n\n* Age 18 to 60 years\n* Clinical diagnosis of medial epicondylitis\n* Symptoms duration ≥6 weeks\n* Pain with resisted wrist flexion\n* Local tenderness at medial epicondyle\n\nExclusion Criteria:\n\n* Previous elbow surgery\n* Corticosteroid injection within the past 3 months\n* Cervical radiculopathy\n* Systemic inflammatory disease\n* Bilateral symptoms","60 Years",{"count":115,"type":22},60,[25],"This randomized controlled trial aims to compare the effectiveness of telerehabilitation and supervised physiotherapy in patients with medial epicondylitis. The primary outcome is improvement in pain and function using the Patient-Rated Elbow Evaluation (PREE). Secondary outcomes include pain intensity, grip strength, musculoskeletal ultrasound findings, adherence, and upper limb disability measured by Quick DASH.",[119,120,121],"Medial Epicondylitis","Telerehabilitation","Physiotherapy",[123,124,125,126,127],"medial epicondylitis","telerehabilitation","grip strength","Patient-Rated Elbow Evaluation","Quick DASH",{"date":40,"type":43},{"date":99,"type":43},{"date":131,"type":22},"2026-12-15",{"name":49,"class":50},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100638203","comparative-outcomes-of-rezm-versus-echolaser-for-treatment-of-benign-prostatic-hyperplasia-with-enlarged-median-lobe-100638203","NCT07578428","Comparative Outcomes of Rezūm Versus EchoLaser for Treatment of Benign Prostatic Hyperplasia With Enlarged Median Lobe.","Comparative Outcomes of Rezūm (Water Vapor Therapy) Versus EchoLaser (Transperineal Laser Ablation) for Treatment of Benign Prostatic Hyperplasia With Enlarged Median Lobe. A Prospective Randomized Comparative Study.","Inclusion Criteria:\n\nInclusion Criteria:\n\nMale patients aged 50 years or older.\n\nDiagnosis of symptomatic BPH with moderate-to-severe lower urinary tract symptoms, defined as an IPSS ≥ 12.\n\nTotal prostate volume between 30 mL and 80 mL, confirmed via Transrectal Ultrasound (TRUS) or mpMRI.\n\nPresence of an enlarged, obstructing intravesical median lobe visualized via imaging or baseline cystoscopy.\n\nPeak urinary flow rate (Qmax) between 5 and 15 mL\u002Fs with a minimum voided volume of ≥ 125 mL.\n\nExclusion Criteria:\n\nConfirmed or suspected prostate cancer (e.g., PSA \\> 4.0 ng\u002FmL without a subsequent negative prostate biopsy or MRI).\n\nHistory of prior surgical interventions for BPH (e.g., TURP, HOLEP, or other MISTs).\n\nPresence of urethral strictures, bladder neck contracture, or established neurogenic bladder dysfunction.\n\nActive urinary tract infection (UTI) or an episode of acute urinary retention requiring an indwelling catheter at the time of screening.\n\nPrevious pelvic radiation therapy or severe pelvic trauma.\n\nInability to safely pause anticoagulant\u002Fantiplatelet therapy per standard hospital perioperative protocols, if applicable.",{"count":141,"type":22},80,[25],"This study evaluates and compares two minimally invasive surgical therapies for treating men with benign prostatic hyperplasia (BPH) who specifically have an enlarged median lobe. The two treatments being compared are Rezūm (water vapor thermal therapy) and EchoLaser (transperineal laser ablation). Participants will be randomized into two equal groups to receive either the Rezūm treatment or the EchoLaser treatment. The primary goal of the study is to evaluate the change in urinary symptoms over a 6-month period using the International Prostate Symptom Score (IPSS). The study will also assess how well each treatment improves urine flow, reduces the size of the prostate, preserves sexual function, and minimizes complications.",[145],"Benign Prostatic Hyperplasia",[147,148],"Rezūm","EchoLaser","2026-05-05",{"date":151,"type":43},"2026-05-11",{"date":153,"type":22},"2026-05-01",{"date":155,"type":22},"2027-05-01",{"name":49,"class":50},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":17,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":51},"100633437","concomitant-trans-perineal-prostate-biopsy-and-ablation-bioblation-for-prostate-cancer-100633437","NCT07526675","Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer","Validation of Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Symptomatic (LUTS) Selected Most Probably Low and Intermediate Risk PCa Patients","Bioblation","Inclusion Criteria:\n\n* Patients with severe Lower Urinary Tract Symptoms (LUTS) meeting the following parameters:\n\n  1. IPSS score \\> 20\n  2. Uroflowmetry flow rate \\\u003C 10 ml\u002Fsec\n  3. Post-void residual \\> 150 cc\n* Patients most probably having low to favorable intermediate-risk prostate cancer, defined as:\n\n  1. PSA level between 4 and 20 ng\u002Fml\n  2. MP-MRI showing 3 or fewer focal lesions\n  3. MP-MRI focal lesions measuring \\\u003C 1.5 cm\n* International or visiting patients requiring early return to their home country due to professional or personal commitments, provided they can undergo short-term management and follow-up coordination\n\nExclusion Criteria:\n\n* Patient PSA level \\> 20 ng\u002Fml\n* More than 3 focal lesions on MP-MRI\n* Metastatic prostate cancer\n* History of lower urinary tract surgery (e.g., TURP, Laser, urinary diversions, artificial urinary sphincter)\n* History of pelvic radiation therapy or radical pelvic surgery","18 Months",{"count":167,"type":22},30,[25],"This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed \"Bioblation\") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.",[171,172,145],"Prostate Cancer","Lower Urinary Tract Symptoms (LUTS)",[171,174,163,175,176,145],"Transperineal Laser Ablation","Focal Therapy","Lower Urinary Tract Symptoms","2026-04-09",{"date":179,"type":43},"2026-04-13",{"date":181,"type":22},"2026-04-10",{"date":183,"type":22},"2026-04-28",{"name":49,"class":50},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":51},"100629850","determination-of-the-optimal-inspiratory-pressure-to-decrease-incidence-of-gastric-insufflation-with-adequate-ventilation-during-facemask-ventilation-in-morbidly-obese-patients-100629850","NCT07480031","Determination of the Optimal Inspiratory Pressure to Decrease Incidence of Gastric Insufflation With Adequate Ventilation During Facemask Ventilation in Morbidly Obese Patients","Ultrasound-Guided Optimization of Inspiratory Pressure During Facemask Ventilation in Morbidly Obese Patients to Prevent Gastric Insufflation: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Adult patients (18-65 years old) scheduled for elective surgery under general anesthesia requiring facemask ventilation.\n\n  * Morbid obesity (BMI ≥40 kg\u002Fm²).\n  * American Society of Anesthesiologists (ASA) physical status II-III.\n  * Normal upper gastrointestinal anatomy (no history of gastric surgery, esophageal strictures, or hiatus hernia).\n  * Fasted for at least 6 hours for solids and 2 hours for fluids (standard preoperative fasting guidelines).\n\nExclusion Criteria:\n\n* • Emergency surgery (due to inability to ensure proper fasting or preoperative assessment).\n\n  * Known or suspected difficult airway (Mallampati class IV, limited neck mobility, or history of difficult intubation).\n  * Gastroesophageal reflux disease (GERD) or high aspiration risk (e.g., pregnancy, symptomatic hiatal hernia).\n  * Contraindications to facemask ventilation (facial trauma, beard\u002Fmask seal interference).\n  * Severe cardiopulmonary disease (e.g., severe COPD, pulmonary hypertension, or unstable angina).\n  * Neuromuscular disorders affecting respiratory function.\n  * Refusal to participate or inability to provide informed consent.","65 Years",{"count":194,"type":22},144,[25],"The goal of this randomized clinical trial is to optimize the inspiratory pressure during facemask ventilation (FMV) in morbidly obese patients (BMI ≥40 kg\u002Fm²), to ensure adequate ventilation while minimizing the risk of gastric insufflation by real-time ultrasound guidance",[198],"Gastric Insufflation","2026-03-14",{"date":201,"type":43},"2026-03-18",{"date":203,"type":22},"2026-04-01",{"date":205,"type":22},"2027-04-15",{"name":49,"class":50},{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":82,"minAge":83,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":51},"100628710","phase-2-intrathecal-bupivacaine-with-or-without-dexmetomidine-for-cesserian-delivery-100628710","NCT07465185","Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery","Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery ;Arandomized Non - Inferiority Study","Inclusion Criteria:\n\n* (1) Full-term pregnant women undergoing elective cesarean section under spinal anesthesia. (2) Age: 20 \\~ 35 years. (3) ASA physical status II \\~ III\n\nExclusion Criteria:\n\n1. Multiple pregnancies.\n2. Cardiovascular disease(e.g., pre-eclampsia and hypertension).\n3. Serious hepatic dysfunction (Child-Pugh class C).\n4. serious renal dysfunction (undergoing dialysis before surgery).\n5. History of alcohol or opioid addiction.\n6. Contraindication to spinal anesthesia.\n7. Refusing to sign informed consent.","35 Years",{"count":216,"type":22},300,[218],"PHASE2","Cesarean section (CS) is one of the most frequently performed surgical procedures globally, with an increasing demand for safe and effective anesthesia techniques. Regional anesthesia, particularly intrathecal anesthesia, has become the method of choice for elective cesarean deliveries.The most commonly used local anesthetic for intrathecal anesthesia is bupivacaine.Recent studies have focused on adjunctive agents to enhance the efficacy of local anesthetics.",[221],"Anesthesia",[223,224,225,226],"bupivacaine","dexmetomedine","spinal anesthesia","cessarian delivery","2026-03-09",{"date":229,"type":43},"2026-03-11",{"date":231,"type":22},"2026-03-15",{"date":233,"type":22},"2026-10-15",{"name":49,"class":50},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":257,"leadSponsor":259,"locationsCount":51},"100628877","phase-3-anterior-iliopsoas-space-block-versus-peng-block-on-ease-of-positioning-for-spinal-anathesia-in-patients-undergoing-hip-surgeries-100628877","NCT07467356","Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip Surgeries","Impact of Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip Surgeries ;Randomized Clinical Trial","Inclusion Criteria:\n\n* (ASA )classes I and II\n* patients of either sex, above the age of 18 who will undergo hip surgeries( (Dynamic hip screw fixation or hemiarthroplasty)(not older than 2 weeks) with persistent pain and scheduled for surgery under SA with an expected duration of 2.5 hours\n\nExclusion Criteria:\n\n* patient's refusal to participate\n* any contraindications to SA or peripheral nerve blocks\n* history of ischemic heart disease\n* patients on opioids for chronic pain\n* patients with significant cognitive impairment.",{"count":85,"type":22},[244],"PHASE3","Total hip arthroplasty (THA) has been one of the most significant advancements in orthopedic surgery over the past century. hip fractures are typically associated with severe pain, effective analgesia is crucial both before and after surgery.Spinal anesthesia (SA) is the most commonly employed method of anesthesia for repairing these fractures.The anterior iliopsoas space block is a considered as a novel technique that targets the lumbosacral trunk as it passes beneath the psoas major muscle, offering potential advantages over the traditional sacral plexus block, which is performed in the supine position.",[247],"Pain Management",[249,250,251,252],"PENG block","anterior iliopsoas space block","ease of positioning","hip surgeries","2026-03-08",{"date":255,"type":43},"2026-03-12",{"date":231,"type":22},{"date":258,"type":22},"2026-09-15",{"name":49,"class":50},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":59,"minAge":267,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":51},"100627011","phase-2-effect-of-dexmedetomidine-dosage-on-postoperative-delirium-in-geriatric-orthopedic-surgery-100627011","NCT07443085","Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery","Dose-Effect Relationship of Dexmedetomidine on Delirium and Cognitive Function After Lower Limb Orthopedic Surgeries for Elderly Patients","Inclusion Criteria:\n\n* Elderly surgical patients.\n* ASA physical status grade II-III.\n* Planned major lower limb orthopedic surgery.\n\nExclusion Criteria:\n\n* pre-existing dementia or drug allergies","55 Years","70 Years",{"count":270,"type":22},75,[218],"This study evaluates the dose-response relationship of Dexmedetomidine (DEX) in reducing the incidence and severity of postoperative delirium (POD) and postoperative cognitive dysfunction (POCD) in elderly patients. The study compares different doses of DEX against a fentanyl control group in patients undergoing major lower limb orthopedic surgery under general anesthesia to determine the optimal dosage for cognitive protection.",[274],"Delirium - Postoperative","2026-02-27",{"date":277,"type":43},"2026-03-02",{"date":279,"type":43},"2026-02-26",{"date":281,"type":22},"2027-10",{"name":49,"class":50},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":82,"minAge":18,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":294,"conditions":295,"keywords":298,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":306,"locationsCount":51},"100622203","melatonin-on-post-operative-pain-after-cs-100622203","NCT07380568","Melatonin on Post Operative Pain After CS","The Effect of Preoperative Oral Melatonin on Postoperative Pain Control After Cesarean Section: A Dose Comparison Study","CS","Inclusion Criteria:\n\n* \\- Women aged 18-40 years.\n* Scheduled for elective cesarean section.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Known hypersensitivity to melatonin or opioids\n* Chronic use of analgesics, sedatives, or antidepressants.\n* History of sleep disorders or psychiatric illness.\n* Complicated pregnancies (e.g., preeclampsia, gestational diabetes).\n* Body mass index (BMI) \\> 35 kg\u002Fm².\n* Emergency cesarean sections.\n* Severe systemic diseases (e.g., liver or kidney dysfunction).","45 Years",{"count":115,"type":22},[25],"The goal of this clinical trial is to learn if melatonin will decrease pain after C.S. The main questions it aims to answer are:\n\nDoes melatonin lower the number of times participants need to use a rescue analgesia? What medical problems do participants have when taking melatonin? Researchers will compare different doses of melatonin to see the ideal dose to decrease pain after C.S.\n\nParticipants will:\n\nTake melatonin 30 min before C.S and will be observed for 24 hours for pain and consumption of other analgesia",[247,296,297],"Pain After Surgery","Cesarean Section Pain",[299],"melatonin and pain after C.S","2026-01-24",{"date":302,"type":43},"2026-02-02",{"date":304,"type":43},"2025-10-10",{"date":203,"type":22},{"name":49,"class":50},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":192,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":51},"100621093","ultrasound-guided-external-oblique-intercostal-plane-block-versus-subcostal-transversus-abdominis-plane-block-for-perioperative-analgesia-in-laparoscopic-sleeve-gastrectomy-100621093","NCT07366138","Ultrasound-Guided External Oblique Intercostal Plane Block Versus Subcostal Transversus Abdominis Plane Block For Perioperative Analgesia in Laparoscopic Sleeve Gastrectomy","Inclusion Criteria:\n\n* Age from 18 to 65 years.\n* Both genders.\n* American Society of Anesthesiologists (ASA) class I or II\n* Body mass index (BMI) between 30-50 kg\u002Fm².\n* Scheduled for elective laparoscopic sleeve gastrectomy under general anesthesia.\n* Written informed consent from patients or surrogate decision makers.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Allergy to local anesthetics.\n* Coagulation disorders or anticoagulant therapy.\n* Local infection or scar at the injection site.\n* Severe hepatic or renal dysfunction.\n* Chronic opioid use or psychiatric illness interfering with pain assessment.\n* Conversion to open surgery or intraoperative complications requiring re-exploration.",{"count":314,"type":22},70,[25],"This study aims to compare the analgesic efficacy, duration of analgesia, and overall opioid consumption between the external oblique intercostal plane (EOIP) block and subcostal transversus abdominis plane (TAP) block in patients undergoing laparoscopic sleeve gastrectomy.",[318,319,320,321,322],"Ultrasound","External Oblique Intercostal Plane Block","Subcostal Transversus Abdominis Plane Block","Perioperative Analgesia","Laparoscopic Sleeve Gastrectomy","2026-01-17",{"date":325,"type":43},"2026-01-26",{"date":327,"type":43},"2025-11-01",{"date":329,"type":22},"2026-11-01",{"name":49,"class":50},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":82,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":353,"leadSponsor":355,"locationsCount":51},"100619378","virtual-reality-versus-intravenous-dexmedetomidine-on-maternal-anxiety-stress-hemodynamics-and-neonatal-outcomes-during-cesarean-section-100619378","NCT07343843","Virtual Reality Versus Intravenous Dexmedetomidine on Maternal Anxiety, Stress, Hemodynamics, and Neonatal Outcomes During Cesarean Section","Effect of Virtual Reality Versus Intravenous Dexmedetomidine on Maternal Anxiety, Stress, Hemodynamics, and Neonatal Outcomes During Cesarean Section","Inclusion Criteria:\n\n* Age over 18 years old.\n* American Society of Anesthesiologists (ASA) physical status II.\n* Scheduled for elective cesarean section (CS) delivery under Central Neuraxial Blockade.\n* Provide informed consent and agree to participate in the study.\n\nExclusion Criteria:\n\n* Patient's refusal\n* Patient known have contraindications for Regional Anesthesia as infection at the site of injection, severe coagulopathy or allergy to local anesthetics.\n* Patient with psychiatric disorders.\n* Sensory impairment (blindness, deafness).\n* Any technical problem preventing proper fitting of the glasses to the patient face.\n* Patients with cognitive impairment, epilepsy or with claustrophobia\n* Patients with suspected eye infection\n* Signs of active labor.\n* Pregnancy related-diseases or antepartum hemorrhage.\n* Presence of Fetal distress.",{"count":339,"type":22},52,[25],"This study aims to compare the efficacy of intravenous dexmedetomidine infusion versus virtual reality (VR) in reducing maternal anxiety, stress, and hemodynamic instability during cesarean section and their effects on neonatal outcome as respiration and heart rate.",[343,344,345,346,347,348,349],"Virtual Reality","Dexmedetomidine","Maternal Anxiety","Stress","Hemodynamics","Neonatal Outcomes","Cesarean Section",{"date":351,"type":43},"2026-01-21",{"date":323,"type":43},{"date":354,"type":22},"2026-07-01",{"name":49,"class":50},{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":82,"minAge":60,"maxAge":113,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":365,"conditions":366,"keywords":372,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":51},"100618669","impact-of-pilates-exercises-on-bone-mineral-density-in-breast-cancer-survivors-receiving-hormonal-therapy-100618669","NCT07334626","Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy","PilatesBCS2026","Inclusion Criteria:\n\n1. Female breast cancer survivors aged 40-60 years.\n2. Histologically confirmed stage I-III breast cancer.\n3. Currently receiving hormonal therapy (aromatase inhibitors) for at least 3 months.\n4. At risk of osteoporosis or with low bone mineral density (BMD) defined by T-score ≤ -1.0 at lumbar spine or hip.\n5. Medically cleared for exercise, specifically low-to-moderate intensity Pilates.\n6. Able to attend supervised exercise sessions three times per week for 12 weeks.\n7. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Metastatic (stage IV) or recurrent breast cancer.\n2. History of osteoporotic fractures in the past 12 months.\n3. Severe cardiovascular, respiratory, or musculoskeletal conditions that contraindicate exercise.\n4. Uncontrolled hypertension, diabetes, or thyroid disorders.\n5. Current use of corticosteroids.\n6. Active bone metabolic disease other than osteoporosis (e.g., Paget's disease, osteomalacia).\n7. Severe cognitive impairment or psychiatric illness preventing adherence to exercise or supplementation.\n8. Known allergy or intolerance to calcium or vitamin D supplementation.\n9. Participation in another clinical trial with structured exercise or bone-targeted intervention within the last 3 months.",{"count":115,"type":22},[25],"Breast cancer survivors receiving endocrine (hormonal) therapy (aromatase inhibitors) are at high risk for cancer treatment-induced bone loss and osteoporosis due to estrogen depletion.",[367,368,369,370,371],"Breast Cancer","Breast Cancer Survivors","Aromatase Inhibitors","Osteoporosis or Osteopenia","Pilates Exercise",[373,374,375,376],"pilates exercises","breast cancer survivors","bone mineral denisty","aromatase inhibitors","2026-01-14",{"date":379,"type":43},"2026-01-15",{"date":381,"type":43},"2026-01-01",{"date":383,"type":22},"2026-09-30",{"name":49,"class":50},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":82,"minAge":18,"maxAge":19,"enrollmentInfo":392,"targetDuration":4,"studyType":394,"phases":4,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":51},"100619608","role-of-circulating-micrornas-in-differentiating-psychological-disorders-among-women-with-chronic-toxoplasmosis-100619608","NCT07346833","Role of Circulating MicroRNAs in Differentiating Psychological Disorders Among Women With Chronic Toxoplasmosis","Deciphering The Role of Circulating MicroRNAs To Differentiate Psychological Disorders Among Women With Chronic Toxoplasmosis","Inclusion Criteria:\n\n* Confirmed psychiatric diagnosis of Schizophrenia (SCZ), Major Depressive Disorder (MDD), or Bipolar Disorder (BD) according to DSM-5 criteria.\n* Seronegative for T. gondii IgM (to ensure infection is not in the acute phase).\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Psychiatric disorders other than Schizophrenia, MDD, and Bipolar Disorder.\n\nSeropositive for T. gondii IgM (indicating acute infection).\n\nRefusal to participate.",{"count":393,"type":22},55,"OBSERVATIONAL","Chronic Toxoplasma gondii (T. gondii) infection is a widespread condition that can negatively affect brain function and is considered a risk factor for various psychiatric conditions, including depression and schizophrenia. This prospective observational study aims to investigate the expression levels of specific circulating microRNAs (miRNAs) in women diagnosed with schizophrenia, major depressive disorder, or bipolar disorder who also have chronic toxoplasmosis. By comparing these levels to patients without the infection, the study seeks to determine if these miRNAs can serve as biological markers to help differentiate between specific psychological disorders and identify the impact of chronic toxoplasmosis on mental health.",[397],"Toxoplasmosis","2026-01-08",{"date":400,"type":43},"2026-01-16",{"date":402,"type":43},"2025-11-20",{"date":404,"type":22},"2026-04",{"name":49,"class":50},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":192,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":423,"locationsCount":51},"100618031","effect-of-dexmedetomidine-on-tear-production-in-angioplasty-patients-100618031","NCT07326332","Effect of Dexmedetomidine on Tear Production in Angioplasty Patients","Effect of Dexmedetomidine Sedation on Tear Film in Patients Undergoing Angioplasty Under Local Anesthesia","Inclusion Criteria:\n\n* Scheduled for elective angioplasty (coronary PCI or peripheral angioplasty) under local anesthesia with planned procedural sedation.\n* Able to give informed consent and complete ocular symptom assessments.\n* Baseline Schirmer I ≥1 mm (to exclude complete anatomic lacrimal failure; you may alter this cutoff).\n\nExclusion Criteria:\n\n* Pre-existing moderate\u002Fsevere dry eye disease or Sjögren's syndrome (history or OSDI \\>33).\n* Ocular surgery within prior 3 months or active ocular infection.\n* Contact lens use within 24 hours before baseline.\n* Chronic systemic medications known to substantially alter lacrimation (recent anticholinergics, high-dose tricyclics) unless stable and documented.\n* Known allergy to dexmedetomidine, midazolam, fentanyl, or propofol.\n* Significant bradycardia (HR \\\u003C50) or high-degree AV block without pacemaker.\n* Pregnancy or breastfeeding.\n* Any condition making study participation or follow-up impossible.",{"count":339,"type":22},[25],"During medical procedures performed under local anesthesia with sedation, such as angioplasty, the eyes may become dry because normal blinking and tear production can be reduced. Dexmedetomidine is a commonly used sedative that provides comfort and pain relief while allowing patients to breathe on their own. However, there is limited information about how dexmedetomidine affects tear production and eye comfort after procedures.\n\nThis study aims to evaluate whether sedation with dexmedetomidine affects tear production compared with standard sedative medications used during angioplasty. Adult patients undergoing angioplasty under local anesthesia will be randomly assigned to receive either dexmedetomidine sedation or standard sedation. Tear production will be measured using the Schirmer test before the procedure, shortly after the procedure, and 12 hours later. Patients will also be asked about eye dryness or discomfort, and any eye-related or sedation-related side effects will be recorded.\n\nThe results of this study may help improve eye safety and comfort in patients receiving sedation during angioplasty and guide the selection of sedative medications in clinical practice.",[417],"Tear Film Alteration","2026-01-02",{"date":398,"type":43},{"date":381,"type":22},{"date":422,"type":22},"2026-06-20",{"name":49,"class":50},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":192,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":51},"100618308","dexamethasone-dexmedetomidine-and-their-combination-on-post-op-git-function-measured-by-i-ffed-score-post-laparoscopic-cholecystectomy-100618308","NCT07329933","Dexamethasone, Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy","Effect of Dexamethasone, Dexmedetomidine and Their Combination on Postoperative Gastrointestinal Function Measured by I-FEED Score After Elective Laparoscopic Cholecystectomy Surgery: a Randomized Controlled Trial","GIT","Inclusion Criteria:\n\n\\- . Age 18-65 years. 2. American Society of Anesthesiologists (ASA) physical status I or II. 3. Scheduled for elective laparoscopic cholecystectomy surgery under general anesthesia.\n\n4\\. Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or contraindication to any study drug (dexamethasone, dexmedetomidine, or placebo).\n\n  2\\. Pre-existing gastrointestinal motility disorders (e.g., gastroparesis, inflammatory bowel disease).\n\n  3\\. Chronic use of opioids, steroids, or antiemetics. 4. History of severe cardiac disease (e.g., high-grade AV block, severe bradycardia).\n\n  5\\. Uncontrolled diabetes mellitus (HbA1c \\> 8.0%). 6. Emergency surgery or conversion to open surgery. 7. Pregnancy or breastfeeding. 8. Morbid obesity (BMI \\>40). 9. Severe hepatic or renal dysfunction.",{"count":21,"type":22},[25],"The goal of this clinical trial is to learn the effect of Dexamethasone and Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy\n\nWhat medical problems do participants have when taking Dexamethasone and Dexmedetomidine? Researchers will compare Dexamethasone and Dexmedetomidine and Their Combination to a placebo (a look-alike substance that contains no drug) to see the effect on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy Participants will receive Dexamethasone 8 mg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Dexmedetomidine 0.5 mcg \u002Fkg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Dexamethasone 8 mg IV + Dexmedetomidine 0.5 mcg\u002Fkg IV+ Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia.\n\nParticipants will receive Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia",[436,437,438,344,439],"GIT Function","Cholecystectomy, Laparoscopic","Dexamethasone","I-FEED Score","2025-12-29",{"date":442,"type":43},"2026-01-09",{"date":444,"type":22},"2025-12-15",{"date":446,"type":22},"2026-06-01",{"name":49,"class":50},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":51},"100617464","autologous-tenons-capsule-graft-for-refractory-macular-holes-100617464","NCT07318961","Autologous Tenon's Capsule Graft for Refractory Macular Holes","Visual and Anatomical Outcomes of Autologous Tenon's Capsule Graft for Refractory Macular Holes","ATCG-RMH","Inclusion Criteria:\n\n* Age 18 years or older\n* Refractory full-thickness macular hole defined as:\n* Chronic macular hole \\>400 µm, or\n* Persistent macular hole following prior vitrectomy with ILM peeling and gas tamponade\n* Clear ocular media and adequate fixation for OCT imaging\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Active ocular infection or inflammation\n* Advanced glaucoma or optic neuropathy\n* History of intraocular tumors\n* Severe proliferative vitreoretinopathy\n* Significant systemic diseases likely to affect visual recovery",{"count":457,"type":22},20,[25],"This prospective interventional study evaluates the anatomical and functional outcomes of autologous Tenon's capsule grafting in patients with refractory full-thickness macular holes. Eligible patients include those with chronic large macular holes (\\>400 µm) or persistent holes following prior pars plana vitrectomy with internal limiting membrane peeling and gas tamponade. Anatomical closure will be assessed using spectral-domain optical coherence tomography, and functional outcomes will be evaluated by best-corrected visual acuity over a 3-month follow-up period.",[461],"Macular Hole Surgery",[463,464],"Autologous Tenon's Capsule Graft","Macular Hole","2025-12-21",{"date":467,"type":43},"2026-01-06",{"date":469,"type":43},"2025-12-14",{"date":471,"type":22},"2026-06-03",{"name":49,"class":50},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":192,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":491,"leadSponsor":492,"locationsCount":51},"100617287","palmitoylethanolamide-vs-ibuprofen-for-pain-after-eswl-100617287","NCT07316660","Palmitoylethanolamide vs Ibuprofen for Pain After ESWL","Palmitoylethanolamide Versus Ibuprofen for Acute Postoperative Pain After Extracorporeal Shock Wave Lithotripsy: A Randomized Trial","Inclusion Criteria:\n\n* Age 18-65 years\n* ASA I or II\n* Undergoing elective ESWL for renal or upper ureteric calculi\n* Expected discharge same day or within 24 hours (outpatient ESWL).\n* Able to provide informed consent and comply with study procedures (including diary\u002FVAS recordings).\n* Not currently taking chronic NSAIDs, opioids, or PEA supplements for ≥7 days prior to ESWL.\n\nExclusion Criteria:\n\n* Chronic pain or daily analgesic use.\n* Known allergy or contraindication to PEA, ibuprofen.\n* Active peptic ulcer disease, known bleeding disorder, anticoagulant therapy\n* Pregnancy or lactation.\n* Use of steroids or other pain-modulating drugs.\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Hepatic failure or significant liver enzyme elevation (AST\u002FALT \\>3× ULN).",{"count":481,"type":22},120,[25],"Pain after extracorporeal shock wave lithotripsy (ESWL), a non-surgical procedure used to treat kidney stones, is common and is usually treated with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. However, NSAIDs may cause side effects in some patients, including stomach irritation and kidney problems.\n\nPalmitoylethanolamide (PEA) is a naturally occurring substance in the body with anti-inflammatory and pain-relieving properties and has been shown to be safe in previous studies. This study aims to compare the effectiveness of PEA with ibuprofen for controlling acute postoperative pain after ESWL.\n\nParticipants undergoing ESWL will be randomly assigned to receive either oral PEA or oral ibuprofen. Pain intensity will be measured using a visual analogue scale during the first 24 hours after the procedure. The use of rescue pain medication and any side effects will also be recorded.\n\nThe results of this study may help determine whether PEA can be an effective alternative to ibuprofen for the management of acute pain after ESWL.",[485,486],"Pain After Extracorporeal Shock Wave Lithotripsy","Palmitoylethanolamide","2025-12-19",{"date":489,"type":43},"2026-01-05",{"date":381,"type":22},{"date":354,"type":22},{"name":49,"class":50},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":501,"sex":59,"minAge":502,"maxAge":18,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":504,"briefSummary":505,"conditions":506,"keywords":508,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":519,"locationsCount":51},"100616067","mirna-in-pediatric-gastritis-100616067","NCT07300787","miRNA in Pediatric Gastritis","Role of miRNA-155 and miRNA-204 in Pediatric Gastritis","microRNA","Inclusion Criteria:\n\nrecurrent abdominal pain warranting upper gastrointestinal endoscopy or gastroscopy including\n\n* peptic-like dyspepsia (identified by two or more symptoms such as periodic pain, pain relief with food or antacid, pre-meal or hunger-induced pain, nausea\u002Fvomiting, and nighttime pain),\n* dysmotility-like dyspepsia (characterized by abdominal distension, anorexia, weight loss, pain worsening with food\u002Fmilk, and belching),\n* and reflux-like dyspepsia (manifesting as heartburn, chest pain\n\nexclusion criteria:\n\n-patients with gastrointestinal disorders explaining abdominal pain (e.g., inflammatory bowel disease, celiac disease, functional abdominal pain)\n\n, -patients on proton pump inhibitors, as well as those with significant medical comorbidities.\n\nExclusion Criteria:\n\n\\-",true,"1 Year",{"count":62,"type":22},[25],"The goal of this clinical trial is to assess the differential expression of miR-155 and miRNA-204 in relation to gastritis, and assess their relation with the presence of H. pylori in children.",[507],"HELICOBACTER PYLORI INFECTIONS",[509,510,511,512],"miRNA-155","miRNA-204","gastritis","H.pylori","2025-12-18",{"date":515,"type":43},"2025-12-24",{"date":517,"type":22},"2026-01-20",{"date":446,"type":22},{"name":49,"class":50},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":394,"phases":4,"briefSummary":527,"conditions":528,"keywords":530,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":51},"100610804","capillary-leak-index-versus-conventional-biomarkers-in-predicting-sepsis-related-outcomes-100610804","NCT07232342","Capillary Leak Index Versus Conventional Biomarkers in Predicting Sepsis-Related Outcomes","Inclusion Criteria:\n\nAge ≥ 18 years.\n\nPostoperative secondary peritonitis requiring ICU admission, with clinical evidence of:\n\nDiffuse or localized abdominal pain\u002Ftenderness. Peritoneal signs (e.g., guarding, rigidity, rebound tenderness). Imaging or intraoperative confirmation of purulent\u002Fexudative intra-abdominal fluid.\n\nSystemic inflammation (e.g., fever, leukocytosis, or vasopressor requirement). Sepsis diagnosis per Sepsis-3 criteria: Suspected\u002Fconfirmed infection with acute increase in SOFA score ≥2 points (6).\n\nAnticipated ICU stay ≥48 hours postoperatively.\n\nExclusion Criteria:\n\n* Pregnancy\n\n  * Advanced liver disease (Child-Pugh class B or C) that might independently affect albumin levels\n  * Advanced kidney disease (CKD stage 4 or 5) or patients on chronic dialysis\n  * Expected mortality within 48 hours of ICU admission\n  * Patients with primary peritonitis or tertiary peritonitis\n  * Immunocompromised patients (e.g., on chronic immunosuppressive therapy, solid organ transplant recipients, patients with HIV and CD4 count \\\u003C200\u002Fmm³)\n  * Patients with pre-existing systemic inflammatory diseases that might affect baseline CRP levels\n  * Patients participating in interventional trials that might affect outcomes",{"count":62,"type":22},"This study aims to evaluate the prognostic significance of CLI in predicting 28-day mortality and other outcomes in critically ill patients who develop post-operative abdominal sepsis.",[529],"Peritonitis Infectious",[531,532,533,534],"Peritonitis","Capillary Leak Index","Conventional Biomarkers","Critically Ill Patients","2025-11-17",{"date":537,"type":43},"2025-11-18",{"date":539,"type":22},"2025-12-10",{"date":541,"type":22},"2026-10-30",{"name":49,"class":50},{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":550,"maxAge":291,"enrollmentInfo":551,"targetDuration":4,"studyType":23,"phases":552,"briefSummary":553,"conditions":554,"keywords":556,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":568,"leadSponsor":569,"locationsCount":4},"100611134","hyaluronic-acid-vs-botulinum-toxin-injection-in-treatment-of-lifelong-drug-resistant-premature-ejaculation-randomized-study-100611134","NCT07236632","Hyaluronic Acid vs Botulinum Toxin Injection in Treatment of Lifelong Drug-Resistant Premature Ejaculation: Randomized Study","Hyaluronic Acid Versus Botox Injection in Treatment of Life Long Drug Resistant Premature Ejaculation. Which is Better? Randomized Study","Inclusion Criteria:\n\n* Adult male patients aged 22 to 45 years.\n* Sexually active and in a stable heterosexual relationship.\n* Circumcised.\n* Able to understand and comply with study procedures and follow-up visits.\n* Diagnosed with lifelong drug-resistant premature ejaculation, defined as persistent ejaculation within one minute of penetration despite prior pharmacologic or behavioral therapy.\n* Normal serum total testosterone, prolactin, and thyroid-stimulating hormone levels.\n* Willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence or history of erectile dysfunction or other sexual or ejaculatory disorders such as retrograde ejaculation or acquired premature ejaculation.\n* History of acute or chronic prostatitis.\n* Any debilitating medical condition including hepatic failure, renal failure, or uncontrolled diabetes mellitus.\n* Previous pelvic or spinal surgery.\n* Prior chemotherapy or radiotherapy.\n* Use of antipsychotic or neuroactive medications that may affect ejaculation.\n* History of substance abuse or current drug dependence.\n* Presence of penile prosthesis, penile deformity, or anatomic abnormalities of the glans or shaft.\n* Known hypersensitivity or allergy to botulinum toxin or hyaluronic acid preparations.\n* Any condition that, in the investigator's opinion, may interfere with the safety or evaluation of the study treatment.","22 Years",{"count":141,"type":22},[25],"Premature ejaculation (PE) is one of the most common male sexual dysfunctions, often resistant to conventional pharmacological and behavioral treatments. This randomized clinical trial aims to compare the safety and efficacy of two minimally invasive treatment options - hyaluronic acid (HA) injection into the glans penis versus botulinum toxin type A injection into the bulbospongiosus muscle - in men with lifelong drug-resistant premature ejaculation. Eighty participants will be randomly assigned in a 1:1 ratio to receive either HA or botulinum toxin injection. The primary outcome is change in intravaginal ejaculatory latency time (IELT). Secondary outcomes include changes in Premature Ejaculation Diagnostic Tool (PEDT), Arabic Index of Premature Ejaculation (AIPE) scores, Premature Ejaculation Profile (PEP), patient satisfaction, and treatment-related adverse events during a 12-month follow-up period.",[555],"Premature Ejaculation",[557,558,559,560,561,562,563],"Hyaluronic Acid","Botulinum Toxins","Ejaculation","Glans Penis","Bulbospongiosus Muscle","Intradermal Injections","Drug Resistance","2025-11-15",{"date":566,"type":43},"2025-11-19",{"date":444,"type":22},{"date":131,"type":22},{"name":49,"class":50},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":192,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":584,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":51},"100608196","effect-of-sedation-after-ultrasound-guided-spinal-anesthesia-on-back-pain-100608196","NCT07198412","Effect of Sedation After Ultrasound-Guided Spinal Anesthesia on Back Pain","Impact of Ultrasound-Guided Spinal Anesthesia and Pre-Procedure Sedation on Postoperative Acute and Chronic Back Pain in Non-Obstetric Surgery.","Inclusion Criteria\n\nAdults aged 18-65 years ASA physical status I-II Body Mass Index (BMI) ≤ 35 kg\u002Fm² Scheduled for elective non-obstetric lower abdominal or lower limb surgery under spinal anesthesia Able to provide written informed consent\n\nExclusion Criteria\n\nContraindications to spinal anesthesia (e.g., coagulopathy, local infection at puncture site) Pre-existing chronic low back pain Chronic opioid use Known allergy or contraindication to study medications (bupivacaine, lidocaine, midazolam) Psychiatric or neurological disorders affecting pain perception or reporting Severe spinal deformities or history of previous spinal surgery Inability to comply with follow-up assessments",{"count":578,"type":22},180,[25],"This study will evaluate whether giving sedation before spinal anesthesia, when performed with ultrasound guidance, reduces the risk of developing back pain after surgery. Spinal anesthesia is commonly used but may cause discomfort or persistent back pain in some patients. By comparing standard techniques, ultrasound guidance, and sedation, we aim to find safer and more comfortable approaches for patients undergoing non-obstetric surgery.",[247,582,583],"Postoperative Acute Pain","Chronic Back Pain",[585,586,587,588,589],"Spinal anesthesia","Ultrasound-guided anesthesia","Pre-procedure sedation","Midazolam","Chronic back pain","2025-11-14",{"date":535,"type":43},{"date":593,"type":43},"2025-10-01",{"date":595,"type":22},"2026-05-10",{"name":49,"class":50},{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":604,"targetDuration":4,"studyType":23,"phases":606,"briefSummary":608,"conditions":609,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":4},"100607941","phase-1-sildosin-as-a-male-contraceptive-non-hormonal-100607941","NCT07195097","Sildosin as a Male Contraceptive Non Hormonal","A Prospective Study to Evaluate the Efficacy of Silodosin 8 mg as an on-Demand, Reversible, Nonhormonal Oral Contraceptive for Males:","Inclusion Criteria:\n\n* male sexually active\n\nExclusion Criteria:\n\n* male on oral contraceptives Male with female partner on contraceptives",{"count":605,"type":22},200,[607],"PHASE1","In all, 200 healthy, sexually active, fertile male candidates will be assigned 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods will be excluded. Follow up data of total spermatozoa per ejaculate, semen volume and Post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups will be recorded. The various side effects reported in the study groups after 12 weeks from the start of the study will be recorded.",[610],"Contraception Use","2025-09-25",{"date":613,"type":43},"2025-09-26",{"date":615,"type":22},"2025-09",{"date":617,"type":22},"2025-12",{"name":49,"class":50},{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":23,"phases":628,"briefSummary":629,"conditions":630,"keywords":634,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":51},"100607111","platelet-rich-plasma-versus-botulinum-toxin-for-refractory-overactive-bladder-a-randomized-trial-100607111","NCT07184307","Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial","Intra-vesical Injection of Platelet-Rich Plasma Compared With Botox for Management of Patients With Refractory Overactive Bladder: A Comparative Randomized Study","Inclusion Criteria:\n\n* Age 18 years or older\n* History of urgency, frequency, nocturia, with or without urge urinary incontinence, lasting for at least 6 months\n* Failure of standard medical treatment (antimuscarinics, beta-3 adrenergic agonists, or other appropriate therapy) for at least 6 months\n* Willing and able to complete bladder diaries, questionnaires, and urodynamic testing\n* Provides informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Previous intravesical biological therapy (e.g., platelet-rich plasma or botulinum toxin)\n* Prior pelvic or bladder surgery that may affect bladder function\n* Active urinary tract infection or sexually transmitted infection\n* Vaginitis or chronic bacterial prostatitis\n* Bladder or lower ureteral stones confirmed by imaging\n* Bladder outlet obstruction on urodynamic study\n* Bladder malignancy (mass on imaging or malignant cells on cytology)\n* Use of indwelling urinary catheter\n* Severe uncontrolled medical conditions (e.g., uncontrolled diabetes, advanced renal or hepatic impairment)\n* Known hypersensitivity to botulinum toxin or contraindication to platelet-rich plasma preparation (e.g., coagulopathy, inability to discontinue anticoagulation safely)",{"count":627,"type":22},48,[25],"Overactive bladder is a common condition that causes sudden urges to urinate, frequent urination, night-time urination, and sometimes leakage of urine. Many people with overactive bladder improve with lifestyle changes and medicines. However, some patients do not respond to these standard treatments and continue to suffer from bothersome symptoms. This study is designed to help patients who have not improved with available medical therapy.\n\nTwo treatments will be compared in this research. The first treatment uses platelet-rich plasma. Platelet-rich plasma is made from a patient's own blood and contains growth factors that may help repair the lining of the bladder and improve bladder function. The second treatment uses botulinum toxin. Botulinum toxin is a protein that can reduce unwanted bladder contractions and is already approved for use in patients with overactive bladder who did not respond to other treatments.\n\nThe purpose of this study is to evaluate whether platelet-rich plasma injection into the bladder wall is safe, effective, and durable when compared with botulinum toxin injection into the bladder muscle. We believe that platelet-rich plasma may improve bladder health by encouraging tissue repair and reducing inflammation, while botulinum toxin may reduce bladder overactivity by blocking chemical signals that cause muscle contractions.\n\nThis study will take place at Benha University Hospital in Egypt. About 48 adult participants with overactive bladder that has not improved after at least six months of medical therapy will be enrolled. Participants will be randomly assigned to one of two groups. One group will receive platelet-rich plasma injections into the bladder lining, and the other group will receive botulinum toxin injections into the bladder muscle. The procedures will be performed under anesthesia using a cystoscope, which is a thin instrument inserted into the bladder.\n\nParticipants will be followed for one year. At several time points during follow-up, they will complete bladder symptom questionnaires, keep a voiding diary, and undergo urodynamic studies to measure bladder capacity and function. Researchers will also monitor safety by recording any side effects, such as urinary tract infections or temporary difficulty emptying the bladder.\n\nThe main goal of this study is to determine whether platelet-rich plasma can reduce symptoms of overactive bladder as effectively as botulinum toxin, with fewer side effects and longer-lasting results. If successful, platelet-rich plasma could offer a new treatment option for patients who continue to struggle with overactive bladder despite standard medical therapy.",[631,632,633],"Overactive Bladder Syndrome","Urinary Urge Incontinence","Detrusor Overactivity",[635,636,637,638,639,640,641,633,642,643],"Platelet-Rich Plasma","Botulinum Toxin Type A","Overactive Bladder","Refractory Overactive Bladder","Urinary Urgency","Urinary Frequency","Urge Urinary Incontinence","Intravesical Injection","Regenerative Therapy","2025-09-13",{"date":646,"type":43},"2025-09-19",{"date":648,"type":43},"2025-04-15",{"date":650,"type":22},"2026-04-15",{"name":49,"class":50},""]